Authored By: Sarah
12 Jul 2024

 High Throughput Screening (HTS) Market Size to grow by USD 19.9 billion between 2024-2028

According to a research report “ High Throughput Screening (HTS) Market” by Application (Target identification and validation, Primary and secondary screening, Toxicology assessment, Stem cell research) End-user (Pharmaceutical and biotechnology companies, Academic and research institutes, CROs) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 19.9 billion, at a CAGR of almost 12.12% during the forecast period. The global research and development (R&D) expenditure in the pharmaceutical sector has experienced consistent growth in recent years, driven by the increasing disease burden in emerging economies. This trend is anticipated to result in the establishment of numerous laboratories and research facilities in these markets during the forecast period. The surge in R&D investments has led to an increase in drug discoveries, with high-throughput screening (HTS) playing a pivotal role. Compared to conventional drug screening methods, HTS offers several advantages, including simplicity, rapid results, cost-effectiveness, and high efficiency. Underpinned by its ligand-target interaction principle, HTS enables the harvesting of extensive data, making it an indispensable tool in modern drug discovery.

Browse market data tables, figures, and in-depth TOC on “High Throughput Screening (HTS) Market” by Application (Target identification and validation, Primary and secondary screening, Toxicology assessment, Stem cell research) End-user (Pharmaceutical and biotechnology companies, Academic and research institutes, CROs) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Application, the Target identification and validation segment is projected to dominate the market size in 2024

In the pharmaceutical and biotechnology sector, the rise of chronic diseases globally necessitates the production of top-tier, regulatory-compliant drugs and therapeutics. Key industry trends include the transition from prescription to over-the-counter medications, a move away from animal testing, and the emergence of personalized medicine. Pharmaceutical giants such as Roche, Novartis, Johnson & Johnson, Pfizer, Sanofi, and Merck have significantly increased their R&D spending to stay competitive. With substantial investments required to bring a drug to market, these companies cannot afford losses from drug failures. High Throughput Screening (HTS) technology plays a pivotal role in reducing costs and increasing efficiency during the drug discovery process, making it an essential tool for pharmaceutical and biotech companies.

By End-user, Pharmaceutical and biotechnology companies  segment is expected to hold the largest market size for the year 2024

In the pharmaceutical industry, the initial stage of drug development encompasses target identification and validation. This crucial process involves the discovery of potential therapeutic targets or drugs for diseases or conditions lacking adequate treatment options. Early and thorough target identification and validation significantly enhance the likelihood of success in subsequent clinical trials. The global burden of chronic diseases, such as cardiovascular diseases, cancer, and respiratory diseases, necessitates continuous advancements in this area. Furthermore, factors including the expanding pipeline for biological candidates, ongoing outsourcing from pharmaceutical companies, and growing regulatory demand for precise analytical data on drugs and process development contribute to the expansion of the target identification and validation market.

North America is forecasted to hold the largest market size by region in 2024

The North American market holds the largest revenue share in the High Throughput Screening (HTS) industry, driven by the presence of prominent players such as Bio-Rad Laboratories and Thermo Fisher Scientific. These companies cater to a substantial number of pharmaceutical and biotechnology firms in the region with a comprehensive range of HTS solutions. The US and Canada are the primary revenue generators within the North American market, attributed to their stable economies, robust infrastructural support, and significant investments in Research and Development (R&D) for the introduction of new drugs and biopharmaceuticals to combat various diseases. These factors collectively fuel the demand for high-quality analytical services in the region.

The High Throughput Screening (HTS) Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Agilent Technologies Inc.
  • Aurora Biomed Inc.
  • Axxam Spa
  • Beckman Coulter Inc.
  • Bio Rad Laboratories Inc.
  • Biomat Srl
  • Charles River Laboratories International Inc.
  • Corning Inc.
  • Danaher Corp.
  • DIANA Biotechnologies s.r.o
  • HighRes Biosolutions
  • JSR Life Sciences LLC
  • Lonza Group Ltd.
  • Merck KGaA
  • NanoTemper Technologies GmbH
  • PerkinElmer Inc.
  • Sygnature Discovery Ltd.
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Global healthcare sector is witnessing a paradigm shift towards High Throughput Screening (HTS) in drug discovery, driven by Pharma companies seeking to accelerate the development of new therapies for various diseases. HTS utilizes open innovation models, enabling collaboration between research organizations, pharmaceutical corporations, biotech startups, and academic institutions. This approach leverages chemical databases, data integration, retrieval, organization, storage, and management systems to screen large compound libraries for potential drug candidates. HTS employs high-resolution imaging systems, microplate readers, and robotic arms to automate the screening process. It's not just limited to new drug discovery but also extends to drug repurposing, as seen with Adcetris from Seagen, which was initially developed for Hodgkin lymphoma but later found to be effective for other types of cancer. HTS plays a crucial role in addressing complex illnesses like neurological disorders, further expanding its application scope. The future of HTS lies in advanced data analytics and continuous innovation to improve efficiency and accuracy in the quest for new therapeutic solutions.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences research sector, particularly in the discovery and development of drugs for chronic diseases. Contract research organizations (CROs) and pharma companies leverage HTS for biochemical screening, cell-based assays, and toxicology studies to identify drug targets and optimize drug development. HTS utilizes label-free technology, lab-on-a-chip, and microplate readers, among other instruments, to screen large compound libraries and analyze genomic data from chemical databases. HTS market encompasses software and services, consumables, and instruments. Software includes data integration, retrieval, organization, storage, and management systems. Collaborative networks and HTS service providers facilitate data sharing and open innovation models. HTS plays a pivotal role in clinical trials, detection techniques, and precision medicine. Technological advancements, such as high-resolution imaging systems, robotic arms, and machine learning, enhance HTS capabilities. Pharmaceutical corporations and biotech startups, as well as academic institutions, collaborate on drug repurposing initiatives, such as Relay Therapeutics, using HTS for target identification and machine learning. The global healthcare sector benefits from HTS in the discovery of new drugs for complex illnesses, including neurological disorders and cancer. Maintenance and specialized equipment are essential for ensuring the reliability and accuracy of HTS technology. The carrier screening market also relies on HTS for genetic testing and drug discovery. Despite the potential for false-positive findings, HTS remains a crucial component of the biopharmaceutical industry's drug development process.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!